- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HAE Market Currents
more »
-
April 30 Haemonetics (HAE): Q1 EPS of $0.80 misses by $0.03. Revenue of $186.7M (+9.8% Y/Y) beats by $3M. (PR)
Comment![Earnings, Healthcare]
HAE Related Articles
more »
HAE News
more »
-
at CNBC.com (Apr 30, 2012)
-
at MarketWatch.com (Apr 30, 2012)
-
at CNBC.com (Apr 30, 2012)
-
at MarketWatch.com (Apr 30, 2012)
-
at MarketWatch.com (Jan 30, 2012)
HAE Press Releases and Filings
more »
-
PR Newswire (Tue, 8:00AM)
-
PR Newswire (May 8, 2012)
-
PR Newswire (May 3, 2012)
-
PR Newswire (Apr 29, 2012)
-
PR Newswire (Apr 29, 2012)
HAE Latest Transcript
more »
HAE Cramer
more »
Currently, there are no Cramer articles on HAE.
HAE Instablog posts
more »
HAE vs. ETF Alternatives
Company Description
Our Company was founded in 1971 and became publicly owned for the first time in 1979. In 1983, American Hospital Supply Corporation (“AHS”) acquired us. When Baxter Travenol Laboratories, Inc. (“Baxter”) acquired AHS in 1985, Baxter divested the Haemonetics business to address antitrust concerns... More